Details for Patent: 7,888,323

Which drugs does patent 7,888,323 protect, and when does it expire?

Patent 7,888,323 protects SYFOVRE and EMPAVELI and is included in two NDAs.

This patent has thirty-three patent family members in eighteen countries.

Summary for Patent: 7,888,323

Title:	Potent compstatin analogs
Abstract:	Compounds comprising peptides and peptidomimetics capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds.
Inventor(s):	Lambris; John D. (Bryn Mawr, PA), Katragadda; Madan (Ypsilanti, MI)
Assignee:	The Trustees Of The University Of Pennsylvania (Philadelphia, PA)
Application Number:	11/605,182
Patent Claim Types: see list of patent claims	Compound;

Understanding the Scope and Claims of United States Patent 7,888,323

Introduction

United States Patent 7,888,323, titled "Potent compstatin analogs," is a significant patent in the field of biomedical research, particularly in the area of complement activation inhibition. This patent, assigned to The Trustees of the University of Pennsylvania, was issued on August 8, 2006, and is set to expire on December 4, 2027.

Inventors and Assignees

The patent was invented by John D. Lambris and Madan Katragadda, and it is assigned to The Trustees of the University of Pennsylvania. This assignment indicates that the university holds the exclusive rights to the inventions described in the patent[4].

Patent Claims

The patent claims are the heart of any patent, as they define the scope of protection granted to the patent holder. Here are some key aspects of the claims in Patent 7,888,323:

Main Claims

• The patent claims cover potent compstatin analogs, which are peptides designed to inhibit the complement system. The complement system is a part of the immune system that helps to clear pathogens from the body, but its dysregulation can lead to various diseases.
• The claims specify the structure and composition of these analogs, including their amino acid sequences and modifications that enhance their binding affinity to C3, a key component of the complement system[4].

Specific Peptide Sequences

• The patent describes the use of a phage-displayed combinatorial random peptide library to identify a 27-residue peptide that binds to C3 and inhibits complement activation. This specific sequence is a crucial part of the invention[4].

Methods of Use

• The patent also claims methods of using these compstatin analogs for therapeutic purposes, such as treating diseases associated with complement activation, including age-related macular degeneration and other inflammatory conditions[4].

Scope of Protection

The scope of protection for Patent 7,888,323 is defined by its claims and the descriptions provided in the patent specification.

Structural Coverage

• The patent protects specific peptide sequences and their derivatives, ensuring that any similar peptides developed by others would infringe on this patent unless they fall outside the claimed scope.
• The structural coverage includes various modifications to the peptides, such as substitutions, deletions, and additions, as long as these modifications do not significantly alter the binding affinity to C3[4].

Functional Coverage

• The patent also covers the functional aspects of the compstatin analogs, including their use in inhibiting complement activation. This means that any method or composition that uses similar peptides for the same purpose could be considered an infringement[4].

Patent Landscape

Understanding the patent landscape around Patent 7,888,323 involves analyzing related patents and the overall intellectual property environment in the field of complement inhibition.

Related Patents

• There are several other patents related to compstatin analogs, such as Patents 10,125,171, 10,875,893, and 11,292,815, which are assigned to Apellis Pharmaceuticals, Inc. These patents cover various aspects of cell-reactive, long-acting, or targeted compstatin analogs and their uses[2][5].
• These related patents indicate a robust and evolving field of research in complement inhibition, with multiple players and ongoing innovations.

Expiration Dates

• Patent 7,888,323 is set to expire on December 4, 2027. This expiration date is crucial for understanding when the exclusive rights to the invention will lapse, allowing others to use the technology without infringement[2][5].

Claim Coverage Matrix and Patent Analytics

To fully understand the coverage and value of Patent 7,888,323, it is beneficial to use patent analytics tools.

Claim Coverage Matrix

• A Claim Coverage Matrix can help in categorizing the patents and claims by scope concepts, linking claims on similar patents. This tool can highlight which patents and claims are actively protecting the intellectual property and where gaps or opportunities exist[3].

Interactive Claim Charts

• Interactive claim charts generated by tools like ClaimScape® can be reviewed by technical experts to determine whether a particular scope concept is applicable to a target product or method. This helps in identifying areas where claim coverage is lacking and future design opportunities[3].

Economic and Strategic Value

The economic and strategic value of Patent 7,888,323 can be significant.

Valuation Methods

• The value of a patent like 7,888,323 can be determined using the cost, income, and market approaches. The income approach, for example, looks at the future benefits provided by the patent, such as licensing fees or savings from using the patented technology[1].

Market Data

• Historical sales data of similar patents can provide insights into their market value. For instance, the sale of patents by IBM and Rockstar Bidco in the past has shown that patents can command high prices, with some deals reaching millions of dollars per patent document[1].

Key Takeaways

• Patent Scope: Patent 7,888,323 covers potent compstatin analogs and their use in inhibiting complement activation.
• Expiration Date: The patent is set to expire on December 4, 2027.
• Related Patents: There are several related patents in the field of complement inhibition, indicating ongoing research and innovation.
• Patent Analytics: Tools like Claim Coverage Matrix and interactive claim charts are essential for understanding the patent landscape and identifying gaps or opportunities.
• Economic Value: The patent's value can be substantial, determined by methods such as the income approach and market data.

FAQs

1. What is the main invention covered by Patent 7,888,323?

   • The main invention covered by Patent 7,888,323 is potent compstatin analogs designed to inhibit the complement system.

2. Who are the inventors and assignees of Patent 7,888,323?

   • The inventors are John D. Lambris and Madan Katragadda, and the assignee is The Trustees of the University of Pennsylvania.

3. What is the expiration date of Patent 7,888,323?

   • The patent is set to expire on December 4, 2027.

4. How can the value of Patent 7,888,323 be determined?

   • The value can be determined using the cost, income, and market approaches, with the income approach looking at future benefits and market data providing insights from similar patent sales.

5. What tools can be used to analyze the patent landscape around Patent 7,888,323?

   • Tools such as Claim Coverage Matrix and interactive claim charts generated by software like ClaimScape® can be used to analyze the patent landscape.

Sources

1. The Value of a Patent - Perpetual Motion Patents
2. Generic Syfovre Availability - Drugs.com
3. Patent Analytics - SLWIP
4. US7888323B2 - Potent compstatin analogs - Google Patents
5. Generic Empaveli Availability - Drugs.com

Drugs Protected by US Patent 7,888,323

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Apellis Pharms	EMPAVELI	pegcetacoplan	SOLUTION;SUBCUTANEOUS	215014-001	May 14, 2021		RX	Yes	Yes				Y
Apellis Pharms	SYFOVRE	pegcetacoplan	SOLUTION;INTRAVITREAL	217171-001	Feb 17, 2023		RX	Yes	Yes				Y

International Family Members for US Patent 7,888,323

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006318333
Brazil	PI0619023
Canada	2631443
Canada	2971349
China	101400692
China	102977191
China	106188239